AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

AC Immune S.A.NASDAQ: ACIU

Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025

Depreciation & amortization growth accelerates

Q4 FY2025 depreciation & amortization of CHF 650.02K rose 22.9% year over year, ahead of the +15.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Depreciation & amortization amounted to 66.9% of revenue in FY2025, up 59.0 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.9% holds above the trailing-twelve-month pace of +15.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 650.02K+6.0% QoQ
Last fiscal yearDec 2025
CHF 2.39M+10.6% YoY
LTMDec 2025
CHF 2.5M+15.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.9%——
1 year+10.6%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CHF · from the cash flow

Latest · FY2025
2.39M CHF
Year-over-year change
+10.6%
4-year CAGR
-0.2%

Depreciation & Amortization vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.5% is the 2nd highest of 9, against a peer median of +2.0%.
  • Depreciation & amortization amounts to 69.9% of revenue for ACIU, versus a peer median of 96.0%.
ACIU Competitors
Depreciation & Amortization for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+3.0%28.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-11.2%33645.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
ANNXAnnexon, Inc.LTM Mar 2026$2.17M USD+0.9%+0.9%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1.23M USD—+8.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.18M USD+9.0%-11.2%236.0%
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026$674K USD+14.4%+24.6%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
AMRNAmarin Corporation plcLTM Mar 2026$97.21K USD-103.3%-0.7%0.0%
Peer median (excluding ACIU) —+2.0%-0.7%96.0%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.